v3.26.1
Pay vs Performance Disclosure - USD ($)
 12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Pay vs Performance Disclosure [Table]          
Pay vs Performance [Table Text Block]
Year  Summary Compensation Table Total for PEO
(1)		   Compensation Actually Paid to PEO
(1)(2)		   Average Summary Compensation Table Total for Other NEOs
(1)		  

Average Compensation

Actually Paid to Other NEOs
(1)(2)

   Total Stockholder Return
(3)		   Peer Group Total Stockholder Return
(4)		   Net Loss
(5)		   Company-Selected Measure (Revenue)
(6)		 
2025  $23,606,274   $33,129,871   $3,563,795   $16,340,716   $714   $120   $5,139,000   $272,303,000 
2024  $1,358,490   $21,472,938   $796,334   $9,025,662   $489   $91   $17,481,000   $199,614,000 
2023  $15,256,463   $3,113,361   $6,472,781   $1,934,673   $163   $92   $24,411,000   $130,193,000 
2022  $1,195,141   $9,511,499   $710,637   $3,053,124   $215   $89   $14,086,000   $88,595,000 
2021  $7,321,467   $8,694,376   $3,014,506   $3,538,146   $126   $99   $18,007,000   $72,476,000 
        
Named Executive Officers, Footnote [Text Block] Mark Baum was our PEO for each year presented.        
Peer Group Issuers, Footnote [Text Block] Peer group TSR represents the cumulative growth of a hypothetical $100 investment made as of December 31, 2020 in the Nasdaq Biotechnology Index, reflected as of the end of each respective year.        
PEO Total Compensation Amount $ 23,606,274 $ 1,358,490 $ 15,256,463 $ 1,195,141 $ 7,321,467
PEO Actually Paid Compensation Amount $ 33,129,871 21,472,938 3,113,361 9,511,499 8,694,376
Adjustment To PEO Compensation, Footnote [Text Block]

 

Adjustments   2025    2024    2023    2022    2021 
CEO – Mark L. Baum – Equity Award Adjustments
Adjustments   2025    2024    2023    2022    2021 
SCT Amounts  $23,606,274   $1,358,490   $15,256,463   $1,195,141   $7,321,467 
(Subtract): Aggregate value for stock awards and option awards included in SCT amounts for the covered fiscal year  $(22,294,873)  $-   $(14,150,821)  $-   $(6,251,841)
Add: Fair value at year end of awards granted during the covered fiscal year that were outstanding and unvested at the covered fiscal year end  $39,052,697   $-   $5,504,217   $-   $6,962,777 
Add (Subtract): Year-over-year change in fair value at covered fiscal year end of awards granted in any prior fiscal year that were outstanding and unvested at the covered fiscal year end  $-   $20,070,948   $-   $7,390,670   $(1,491,366)
Add: Vesting date fair value of awards granted and vested during the covered fiscal year  $-   $-   $-   $-   $- 
(Subtract) Add: Change as of the vesting date (from the end of the prior fiscal year) in fair value of awards granted in any prior fiscal year for which vesting conditions were satisfied during the covered fiscal year  $(7,234,227)  $43,500   $(3,496,498)  $925,688   $2,153,339 
Add: Fair value at end of prior fiscal year of awards granted in any prior fiscal year that failed to meet the applicable vesting conditions during the covered fiscal year  $-   $-   $-   $-   $- 
Add: Dividends or other earnings paid on stock or option awards in the covered fiscal year prior to vesting if not otherwise included in the total compensation for the covered fiscal year  $-   $-   $-   $-   $- 
CAP Amounts (as calculated)  $33,129,871   $21,472,938   $3,113,361   $9,511,499   $8,694,376 

 

 

Adjustments  2025*   2024*   2023*   2022*   2021* 
Non-CEO Equity Award Adjustments*
Adjustments  2025   2024   2023   2022   2021 
SCT Amounts  $3,563,795   $796,334   $6,472,781   $710,637   $3,014,506 
(Subtract): Aggregate value for stock awards and option awards included in SCT amounts for the covered fiscal year  $(2,973,779)  $-   $(5,788,972)  $-   $(2,345,183)
Add: Fair value at year end of awards granted during the covered fiscal year that were outstanding and unvested at the covered fiscal year end  $19,872,664   $-   $2,251,725   $-   $2,642,227 
Add (Subtract): Year-over-year change in fair value at covered fiscal year end of awards granted in any prior fiscal year that were outstanding and unvested at the covered fiscal year end  $-   $8,210,842   $-   $1,948,868   $46,479 
Add: Vesting date fair value of awards granted and vested during the covered fiscal year  $-   $-   $-   $-   $- 
(Subtract) Add: Change as of the vesting date (from the end of the prior fiscal year) in fair value of awards granted in any prior fiscal year for which vesting conditions were satisfied during the covered fiscal year  $(4,121,964)  $18,486   $(1,000,861)  $393,619   $180,117 
Add: Fair value at end of prior fiscal year of awards granted in any prior fiscal year that failed to meet the applicable vesting conditions during the covered fiscal year  $-   $-   $-   $-   $- 
Add: Dividends or other earnings paid on stock or option awards in the covered fiscal year prior to vesting if not otherwise included in the total compensation for the covered fiscal year  $-   $-   $-   $-   $- 
CAP Amounts (as calculated)  $16,340,716   $9,025,662   $1,934,673   $3,053,124   $3,538,146 

 

*The Non-CEO named executive officers for 2025 include Andrew R. Boll, John P. Saharek, Francis W. Mullery and Amir H. Shojaei, and for 2024 through 2021 include Andrew R. Boll and John P. Saharek.
       
Non-PEO NEO Average Total Compensation Amount [1],[2] $ 3,563,795 796,334 6,472,781 710,637 3,014,506
Non-PEO NEO Average Compensation Actually Paid Amount [1],[2],[3] $ 16,340,716 9,025,662 1,934,673 3,053,124 3,538,146
Compensation Actually Paid vs. Total Shareholder Return [Text Block]

Relationship Between Compensation Actually Paid and TSR

 

As illustrated in the table above, compensation actually paid to our PEO and Non-PEO NEOs fluctuates from year to year, in part due to changes in the Company’s stock price and in part due to fluctuations in equity awards granted to our NEOs year-to-year. Because equity awards are revalued based on stock price performance, increases in our stock price generally result in higher compensation actually paid, while decreases in stock price generally result in lower compensation actually paid.

 

Although TSR is not used as a direct input in determining compensation, the Compensation Committee believes that the use of equity-based compensation aligns executive interests with those of stockholders by linking a substantial portion of compensation to stock price performance over time.

        
Relationship Between Compensation Actually Paid and Net Loss

Relationship Between Compensation Actually Paid and Net Loss

 

The Company has historically reported net losses as it continues to invest in the growth of its business, including commercial expansion, product development and strategic initiatives. As a result, net loss is not used by the Compensation Committee as a primary measure in determining executive compensation.

 

Instead, the Compensation Committee evaluates performance based on metrics it believes better reflect the Company’s operating progress and long-term value creation, including revenue, adjusted EBITDA, product performance and key strategic initiatives, which are also reflected in the Company’s selected performance measures for purposes of the pay-versus-performance disclosure. Accordingly, compensation actually paid to our named executive officers is not directly correlated with net loss.

        
Relationship Between Compensation Actually Paid and Revenue

Relationship Between Compensation Actually Paid and Revenue

 

The Company has identified Revenue as its Company-Selected Measure, which represents the most important financial performance measure used to link executive compensation actually paid to Company performance.

 

Compensation actually paid to our PEO and Non-PEO NEOs is influenced by this measure primarily through our annual incentive compensation program, which is designed to reward achievement of key financial and operational objectives.

 

In general:

 

●When the Company achieves or exceeds its performance targets for this measure, annual incentive payouts increase, contributing to higher compensation actually paid; and
●When performance falls below target levels, incentive payouts are reduced, resulting in lower compensation actually paid.

 

The Compensation Committee selected this measure because it reflects the Company’s operational performance and growth and is a key driver of long-term stockholder value.

        
Relationship Between Company Performance and Peer Group TSR

Relationship Between Company Performance and Peer Group TSR

 

The Company’s TSR is compared to the TSR of the Nasdaq Biotechnology Index, as required by SEC rules. The peer group TSR is calculated using the same methodology as the Company’s TSR and provides context for evaluating relative stockholder return performance.

 

While the Compensation Committee does not directly benchmark compensation decisions to peer group TSR, it considers overall market conditions and relative performance in evaluating the competitiveness and effectiveness of the Company’s executive compensation program.

        
Total Shareholder Return Amount [4] $ 714 489 163 215 126
Peer Group Total Shareholder Return Amount [5] 120 91 92 89 99
Net Income (Loss) Attributable to Parent [6] $ 5,139,000 $ 17,481,000 $ 24,411,000 $ 14,086,000 $ 18,007,000
Company Selected Measure Amount [7] (272,303,000) (199,614,000) (130,193,000) (88,595,000) (72,476,000)
PEO Name Mark Baum Mark Baum Mark Baum Mark Baum Mark Baum
Measure [Axis]: 1          
Pay vs Performance Disclosure [Table]          
Tabular List of Most Important Performance Measures

Tabular List of Most Important Performance Measures

 

The following represents the most important financial and non-financial performance measures used by the Company to link executive compensation actually paid to Company performance for the most recently completed fiscal year:

 

●Revenue;
●Strategic and operational milestones;
●Product development and commercialization objectives; and
●Individual performance objectives.
        
PEO [Member]          
Pay vs Performance Disclosure [Table]          
PEO Total Compensation Amount [1] $ 23,606,274 $ 1,358,490 $ 15,256,463 $ 1,195,141 $ 7,321,467
PEO [Member] | Aggregate Value for Stock Awards and Option Awards included in SCT Amounts for the Covered Fiscal Year [Member]          
Pay vs Performance Disclosure [Table]          
Adjustment to Compensation Amount (22,294,873) (14,150,821) (6,251,841)
PEO [Member] | Fair Value at Year End of Awards Granted During the Covered Fiscal Year That Were Outstanding and Unvested at the Covered Fiscal Year End [Member]          
Pay vs Performance Disclosure [Table]          
Adjustment to Compensation Amount 39,052,697 5,504,217 6,962,777
PEO [Member] | Year Over Year Change in Fair Value at Covered Fiscal Year End of Awards Granted in Any Prior Fiscal Year That Were Outstanding and Unvested at the Covered Fiscal Year End [Member]          
Pay vs Performance Disclosure [Table]          
Adjustment to Compensation Amount 20,070,948 7,390,670 (1,491,366)
PEO [Member] | Vesting Date Fair Value of Awards Granted and Vested During the Covered Fiscal Year [Member]          
Pay vs Performance Disclosure [Table]          
Adjustment to Compensation Amount
PEO [Member] | Change As of the Vesting Date From the End of the Prior Fiscal Year in Fair Value of Awards Granted in Any Prior Fiscal Year for Which Vesting Conditions Were Satisfied During the Covered Fiscal Year [Member]          
Pay vs Performance Disclosure [Table]          
Adjustment to Compensation Amount (7,234,227) 43,500 (3,496,498) 925,688 2,153,339
PEO [Member] | Fair Value at End of Prior Fiscal Year of Awards Granted in Any Prior Fiscal Year That Failed to Meet the Applicable Vesting Conditions During the Covered Fiscal Year [Member]          
Pay vs Performance Disclosure [Table]          
Adjustment to Compensation Amount
PEO [Member] | Dividends Or Other Earnings Paid on Stock Or Option Awards in the Covered Fiscal Year Prior to Vesting If Not Otherwise included in the total Compensation for the Covered Fiscal Year [Member]          
Pay vs Performance Disclosure [Table]          
Adjustment to Compensation Amount
Non-PEO NEO [Member] | Aggregate Value for Stock Awards and Option Awards included in SCT Amounts for the Covered Fiscal Year [Member]          
Pay vs Performance Disclosure [Table]          
Adjustment to Compensation Amount [2] (2,973,779) (5,788,972) (2,345,183)
Non-PEO NEO [Member] | Fair Value at Year End of Awards Granted During the Covered Fiscal Year That Were Outstanding and Unvested at the Covered Fiscal Year End [Member]          
Pay vs Performance Disclosure [Table]          
Adjustment to Compensation Amount [2] 19,872,664 2,251,725 2,642,227
Non-PEO NEO [Member] | Year Over Year Change in Fair Value at Covered Fiscal Year End of Awards Granted in Any Prior Fiscal Year That Were Outstanding and Unvested at the Covered Fiscal Year End [Member]          
Pay vs Performance Disclosure [Table]          
Adjustment to Compensation Amount [2] 8,210,842 1,948,868 46,479
Non-PEO NEO [Member] | Vesting Date Fair Value of Awards Granted and Vested During the Covered Fiscal Year [Member]          
Pay vs Performance Disclosure [Table]          
Adjustment to Compensation Amount [2]
Non-PEO NEO [Member] | Change As of the Vesting Date From the End of the Prior Fiscal Year in Fair Value of Awards Granted in Any Prior Fiscal Year for Which Vesting Conditions Were Satisfied During the Covered Fiscal Year [Member]          
Pay vs Performance Disclosure [Table]          
Adjustment to Compensation Amount [2] (4,121,964) 18,486 (1,000,861) 393,619 180,117
Non-PEO NEO [Member] | Fair Value at End of Prior Fiscal Year of Awards Granted in Any Prior Fiscal Year That Failed to Meet the Applicable Vesting Conditions During the Covered Fiscal Year [Member]          
Pay vs Performance Disclosure [Table]          
Adjustment to Compensation Amount [2]
Non-PEO NEO [Member] | Dividends Or Other Earnings Paid on Stock Or Option Awards in the Covered Fiscal Year Prior to Vesting If Not Otherwise included in the total Compensation for the Covered Fiscal Year [Member]          
Pay vs Performance Disclosure [Table]          
Adjustment to Compensation Amount [2]
[1] Mark Baum was our PEO for each year presented.
[2] The Non-CEO named executive officers for 2025 include Andrew R. Boll, John P. Saharek, Francis W. Mullery and Amir H. Shojaei, and for 2024 through 2021 include Andrew R. Boll and John P. Saharek.
[3] The following tables set forth adjustments made during each year presented to arrive at the CAP Amounts for our PEO and Other NEOs, respectively, during each year:
[4] Total Stockholder Return (“TSR”) represents the cumulative growth of a hypothetical $100 investment in the Company made as of December 31, 2020, reflected as of the end of each respective year.
[5] Peer group TSR represents the cumulative growth of a hypothetical $100 investment made as of December 31, 2020 in the Nasdaq Biotechnology Index, reflected as of the end of each respective year.
[6] Represents the amount of net loss reflected in our consolidated financial statements for each covered fiscal year.
[7] The Company selected revenue as its most important financial performance measure because it reflects the Company’s commercial growth and operational execution, which are key drivers of long-term stockholder value.